A Double-blind, Randomised, Placebo Controlled (Within a Dose Group) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses (5 µg, 10 µg and 20 µg) of BI 1744 CL for 14 Days in Healthy Male Volunteers
Latest Information Update: 28 Jun 2014
At a glance
- Drugs Olodaterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 28 Jun 2014 New trial record